FDA Approves FluMist's Use in Young Children - - BioPharm International

ADVERTISEMENT

FDA Approves FluMist's Use in Young Children

BioPharm Bulletin

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2–5. Approval for the vaccine was previously limited to healthy children 5 years of age and older and adults up to age 49.

Before this approval, there were only two vaccines licensed in the US for children under the age of 5. One of the vaccines, Fluzone, is indicated for people over 6 months of age, while Fluvirin, the other vaccine, is for use in children age 4 and older.

FDA release

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here